Upjohn INDs
Executive Summary
Company predicts seven IND applications will be filed before the end of 1990. Five INDs have been filed so far this year. Three were sent to FDA in January -- for U-73975, an antineoplastic, and trospectomycin vaginal cream and suppository for bacterial vaginosis; one in February, for the lazaroid U-76006F for spinal cord injury; and one in March, for the oral anticonvulsant compound U-54494A. An IND for the I.V. form of the drug is slated for filing in the third quarter, and Upjohn is forecasting the filing of soluble CD4-PE40 for AIDS in the fourth quarter of 1990. Another soluble CD4 (U-84796) will get an IND filing in the first quarter of 1991.